- Home
- FOF vs IMAB Comparison
FOF vs IMAB Comparison
Compare FOF & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOF
- IMAB
- Stock Information
- Founded
- FOF 2006
- IMAB 2014
- Country
- FOF United States
- IMAB United States
- Employees
- FOF N/A
- IMAB N/A
- Industry
- FOF Investment Managers
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- FOF Finance
- IMAB Health Care
- Exchange
- FOF Nasdaq
- IMAB Nasdaq
- Market Cap
- FOF 354.8M
- IMAB 394.2M
- IPO Year
- FOF N/A
- IMAB 2020
- Fundamental
- Price
- FOF $13.07
- IMAB $4.32
- Analyst Decision
- FOF
- IMAB Strong Buy
- Analyst Count
- FOF 0
- IMAB 6
- Target Price
- FOF N/A
- IMAB $7.17
- AVG Volume (30 Days)
- FOF 58.7K
- IMAB 1.6M
- Earning Date
- FOF 01-01-0001
- IMAB 11-02-2025
- Dividend Yield
- FOF 9.07%
- IMAB N/A
- EPS Growth
- FOF N/A
- IMAB N/A
- EPS
- FOF N/A
- IMAB N/A
- Revenue
- FOF N/A
- IMAB N/A
- Revenue This Year
- FOF N/A
- IMAB N/A
- Revenue Next Year
- FOF N/A
- IMAB N/A
- P/E Ratio
- FOF N/A
- IMAB N/A
- Revenue Growth
- FOF N/A
- IMAB N/A
- 52 Week Low
- FOF $9.59
- IMAB $0.60
- 52 Week High
- FOF $11.75
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- FOF 56.41
- IMAB 58.60
- Support Level
- FOF $12.98
- IMAB $3.40
- Resistance Level
- FOF $13.12
- IMAB $4.02
- Average True Range (ATR)
- FOF 0.10
- IMAB 0.29
- MACD
- FOF 0.01
- IMAB 0.04
- Stochastic Oscillator
- FOF 87.50
- IMAB 82.88
About FOF Cohen & Steers Closed-End Opportunity Fund Inc.
Cohen & Steers Closed-end Opp Fd Inc is a diversified, closed-ended management investment company. Its investment objective is to achieve a total return, consisting of high current income and potential capital appreciation.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).